Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  prednisone
Find trials that include:  Any drugs shown
Results 1-25 of 81 for your search:
Start Over
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 30 to 70
Trial IDs: E1910, NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01, NCT02003222
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR104761, NCI-2015-01729, 2014-002272-88, 54767414MMY3007, NCT02195479
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 80
Trial IDs: CC-5013-DLC-002, NCI-2015-00282, 2013-004054-21, NCT02285062
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756, NCT02883049
Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: PCYC-1140-IM, NCI-2017-00036, NCT02959944
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 2 to 21
Trial IDs: AALL1631, NCI-2016-01588, NCT03007147
Lenalidomide, Rituximab, Cyclophosphamide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Diffuse Large Cell or Grade 3A/B Follicular B-Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC078E, NCI-2009-01196, Celgene #RV-NHL-PI-0325, RV-NHL-PI-0325, MAYO-MC078E, NCT00670358
Cabozantinib-S-Malate, Docetaxel, and Prednisone in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9243, NCI-2013-01554, 120204, P11901, 12-C-0204, NCT01683994
A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO27878, NCI-2016-00590, NCT02055820
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE3413, NCI-2014-00249, NCT02073097
Lenalidomide and Combination Chemotherapy in Treating Patients with MYC-Associated B-Cell Lymphomas
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-1406, NCI-2014-01581, IRB13-1406, NCT02213913
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, P131448, NCT02356159
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521, NCI-2015-00779, NCT02420717
Ofatumumab and Prednisone in Treating Patients with Chronic Graft-Versus-Host Disease
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17071, NCI-2012-02451, 00008286, COMB157EUS03T, NCT01680965
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients with Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H09, NCI-2015-00400, STU00200596, X16042, NCT02481310
Enzalutamide and Cabazitaxel in Treating Patients with Metastatic, Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00011227, NCI-2015-01103, 11227, CRS00001390, NCT02522715
Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 145515, NCI-2015-01797, 15-15745, CLEE011XUS07T, NCI-2015-01701, NCT02494921
Combination Chemotherapy and Lenalidomide in Treating Patients with Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 511-14, NCI-2015-00088, RV-CL-PTCL-PI-003858, NCT02561273
Lenalidomide, Combination Chemotherapy, and Rituximab in Treating Patients with Primary Effusion Lymphoma or KSHV-Associated Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0171, NCI-2016-01483, P162804, NCT02911142
Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2006-0328, NCI-2012-01518, NCT00501826
Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HOD08, NCI-2009-01138, NCT00846742
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage IA-IIB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB-50801, NCI-2011-02034, CDR0000669076, NCT01118026
Start Over